Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anastomotic Leak | 14 | 2023 | 104 | 3.370 |
Why?
|
| Colorectal Surgery | 3 | 2023 | 22 | 2.280 |
Why?
|
| Proctocolectomy, Restorative | 7 | 2025 | 105 | 2.170 |
Why?
|
| Colorectal Neoplasms | 8 | 2024 | 979 | 1.890 |
Why?
|
| Enterococcus faecalis | 7 | 2022 | 54 | 1.850 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2022 | 77 | 1.470 |
Why?
|
| Rectal Neoplasms | 6 | 2024 | 129 | 1.450 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2022 | 128 | 1.190 |
Why?
|
| Pouchitis | 3 | 2025 | 54 | 1.050 |
Why?
|
| Colitis, Ulcerative | 8 | 2025 | 760 | 1.000 |
Why?
|
| Microbiota | 7 | 2023 | 410 | 0.970 |
Why?
|
| Colectomy | 3 | 2020 | 175 | 0.950 |
Why?
|
| Surgeons | 4 | 2022 | 249 | 0.940 |
Why?
|
| Colon | 9 | 2022 | 521 | 0.930 |
Why?
|
| Elective Surgical Procedures | 3 | 2020 | 129 | 0.920 |
Why?
|
| Colonic Pouches | 5 | 2025 | 85 | 0.910 |
Why?
|
| Gastrointestinal Microbiome | 6 | 2021 | 522 | 0.870 |
Why?
|
| Anastomosis, Surgical | 10 | 2023 | 277 | 0.860 |
Why?
|
| Surgical Wound Infection | 2 | 2022 | 204 | 0.820 |
Why?
|
| Postoperative Complications | 9 | 2025 | 2317 | 0.810 |
Why?
|
| Laxatives | 1 | 2021 | 13 | 0.760 |
Why?
|
| Colonic Neoplasms | 2 | 2024 | 571 | 0.750 |
Why?
|
| Anti-Bacterial Agents | 5 | 2022 | 800 | 0.730 |
Why?
|
| Ileus | 1 | 2020 | 9 | 0.700 |
Why?
|
| Intestines | 6 | 2020 | 416 | 0.700 |
Why?
|
| Vital Signs | 1 | 2020 | 37 | 0.700 |
Why?
|
| Colonic Diseases | 1 | 2019 | 61 | 0.640 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 110 | 0.630 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 1169 | 0.620 |
Why?
|
| Betacoronavirus | 1 | 2020 | 262 | 0.560 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 206 | 0.550 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 345 | 0.550 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 700 | 0.550 |
Why?
|
| Collagen | 3 | 2021 | 294 | 0.520 |
Why?
|
| Humans | 45 | 2025 | 90014 | 0.500 |
Why?
|
| Rectum | 3 | 2022 | 148 | 0.500 |
Why?
|
| Risk Assessment | 3 | 2019 | 2327 | 0.490 |
Why?
|
| Quality Improvement | 1 | 2019 | 457 | 0.490 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.480 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2025 | 594 | 0.480 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 86 | 0.480 |
Why?
|
| Retrospective Studies | 14 | 2025 | 9239 | 0.440 |
Why?
|
| Laparoscopy | 1 | 2020 | 780 | 0.430 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2023 | 251 | 0.410 |
Why?
|
| Intestinal Mucosa | 3 | 2018 | 806 | 0.390 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 374 | 0.380 |
Why?
|
| Diet, Western | 2 | 2023 | 38 | 0.380 |
Why?
|
| Phenotype | 6 | 2025 | 2458 | 0.370 |
Why?
|
| Plasminogen | 2 | 2021 | 45 | 0.360 |
Why?
|
| Risk Factors | 6 | 2022 | 5566 | 0.350 |
Why?
|
| Crohn Disease | 4 | 2022 | 764 | 0.290 |
Why?
|
| Dysbiosis | 2 | 2020 | 81 | 0.280 |
Why?
|
| Dinucleotide Repeats | 1 | 2006 | 14 | 0.270 |
Why?
|
| Bacteria | 4 | 2023 | 486 | 0.260 |
Why?
|
| Mice | 7 | 2023 | 11869 | 0.260 |
Why?
|
| Viral Envelope Proteins | 1 | 2006 | 94 | 0.260 |
Why?
|
| Oligonucleotides | 1 | 2006 | 92 | 0.250 |
Why?
|
| Mice, Inbred BALB C | 3 | 2023 | 1091 | 0.250 |
Why?
|
| Animals | 14 | 2023 | 27551 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1350 | 0.250 |
Why?
|
| Simplexvirus | 1 | 2006 | 151 | 0.240 |
Why?
|
| Male | 14 | 2025 | 42705 | 0.240 |
Why?
|
| Collagenases | 2 | 2022 | 41 | 0.240 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2022 | 51 | 0.240 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2021 | 203 | 0.230 |
Why?
|
| Tranexamic Acid | 2 | 2021 | 38 | 0.220 |
Why?
|
| Incidence | 3 | 2019 | 1604 | 0.210 |
Why?
|
| Hypoalbuminemia | 1 | 2022 | 9 | 0.210 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 475 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2006 | 482 | 0.200 |
Why?
|
| Anus Diseases | 1 | 2022 | 15 | 0.200 |
Why?
|
| Rectal Fistula | 1 | 2022 | 18 | 0.200 |
Why?
|
| Malnutrition | 1 | 2022 | 33 | 0.200 |
Why?
|
| Pressure Ulcer | 1 | 2022 | 43 | 0.200 |
Why?
|
| Adult | 9 | 2025 | 26845 | 0.200 |
Why?
|
| Anus Neoplasms | 1 | 2022 | 36 | 0.200 |
Why?
|
| Female | 12 | 2025 | 46620 | 0.200 |
Why?
|
| Middle Aged | 8 | 2025 | 26179 | 0.190 |
Why?
|
| Illinois | 2 | 2021 | 485 | 0.190 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 40 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 2395 | 0.180 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 199 | 0.180 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.170 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2020 | 1496 | 0.170 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 104 | 0.170 |
Why?
|
| Collagen Type IV | 1 | 2019 | 26 | 0.170 |
Why?
|
| Fibrinolysis | 1 | 2019 | 37 | 0.170 |
Why?
|
| Preoperative Period | 1 | 2019 | 94 | 0.170 |
Why?
|
| Collagen Type I | 1 | 2019 | 72 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2019 | 27 | 0.160 |
Why?
|
| Wound Healing | 2 | 2019 | 362 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 51 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2021 | 395 | 0.160 |
Why?
|
| Propensity Score | 1 | 2019 | 149 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1869 | 0.150 |
Why?
|
| Caenorhabditis elegans | 3 | 2015 | 231 | 0.150 |
Why?
|
| Registries | 2 | 2021 | 809 | 0.150 |
Why?
|
| Colitis | 1 | 2021 | 247 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 3682 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2021 | 2886 | 0.140 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 174 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2020 | 872 | 0.140 |
Why?
|
| Rats, Wistar | 2 | 2015 | 303 | 0.140 |
Why?
|
| Biological Products | 1 | 2019 | 161 | 0.140 |
Why?
|
| Rats | 4 | 2020 | 4048 | 0.140 |
Why?
|
| Aged | 5 | 2021 | 19269 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1731 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 437 | 0.140 |
Why?
|
| Patient Safety | 1 | 2019 | 219 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 2 | 2019 | 237 | 0.140 |
Why?
|
| United States | 4 | 2024 | 7115 | 0.130 |
Why?
|
| Prevalence | 1 | 2020 | 1250 | 0.130 |
Why?
|
| Gastrointestinal Motility | 1 | 2016 | 25 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 1096 | 0.130 |
Why?
|
| Reoperation | 1 | 2018 | 605 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 91 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1703 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2016 | 155 | 0.120 |
Why?
|
| Mutation | 3 | 2013 | 4169 | 0.120 |
Why?
|
| Young Adult | 3 | 2025 | 6423 | 0.120 |
Why?
|
| Household Articles | 1 | 2014 | 15 | 0.120 |
Why?
|
| Hospitals | 1 | 2017 | 303 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1183 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 778 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 953 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2024 | 8295 | 0.110 |
Why?
|
| Ischemia | 1 | 2015 | 253 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1008 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2769 | 0.100 |
Why?
|
| Family | 1 | 2014 | 324 | 0.100 |
Why?
|
| Adolescent | 3 | 2021 | 9352 | 0.100 |
Why?
|
| Suture Techniques | 1 | 2013 | 144 | 0.100 |
Why?
|
| Macrophages | 1 | 2015 | 582 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2020 | 4326 | 0.090 |
Why?
|
| Cell Line | 1 | 2015 | 2495 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6784 | 0.090 |
Why?
|
| Chemoradiotherapy | 2 | 2024 | 305 | 0.090 |
Why?
|
| Medical Oncology | 2 | 2024 | 384 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1681 | 0.080 |
Why?
|
| Carcinogenesis | 2 | 2023 | 216 | 0.080 |
Why?
|
| Virulence | 2 | 2020 | 282 | 0.080 |
Why?
|
| Rib Fractures | 1 | 2008 | 8 | 0.080 |
Why?
|
| Endoscopy | 2 | 2022 | 352 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 3257 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 1998 | 0.070 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2008 | 113 | 0.070 |
Why?
|
| Inflammation | 2 | 2023 | 982 | 0.070 |
Why?
|
| Thymine | 1 | 2006 | 17 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 48 | 0.070 |
Why?
|
| Thionucleotides | 1 | 2006 | 55 | 0.070 |
Why?
|
| Vero Cells | 1 | 2006 | 103 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2008 | 162 | 0.070 |
Why?
|
| Guanine | 1 | 2006 | 207 | 0.060 |
Why?
|
| Prognosis | 2 | 2025 | 3794 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2416 | 0.060 |
Why?
|
| Colostomy | 1 | 2022 | 13 | 0.050 |
Why?
|
| Rectovaginal Fistula | 1 | 2022 | 7 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 129 | 0.050 |
Why?
|
| Abscess | 1 | 2022 | 94 | 0.050 |
Why?
|
| Disease Management | 1 | 2024 | 328 | 0.050 |
Why?
|
| Enema | 1 | 2021 | 39 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2021 | 60 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2021 | 280 | 0.050 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 301 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 34 | 0.040 |
Why?
|
| Infliximab | 1 | 2020 | 159 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2020 | 151 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2019 | 40 | 0.040 |
Why?
|
| Proteolysis | 1 | 2019 | 114 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 99 | 0.040 |
Why?
|
| Telemedicine | 1 | 2021 | 195 | 0.040 |
Why?
|
| Long Term Adverse Effects | 1 | 2018 | 6 | 0.040 |
Why?
|
| Vitamin D | 1 | 2021 | 269 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 693 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1148 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2671 | 0.040 |
Why?
|
| Propionibacterium | 1 | 2017 | 6 | 0.040 |
Why?
|
| Staphylococcus | 1 | 2017 | 24 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 741 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2019 | 281 | 0.040 |
Why?
|
| Time Factors | 1 | 2006 | 5362 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2020 | 1074 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 853 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 301 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 1059 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 382 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 979 | 0.030 |
Why?
|
| Beds | 1 | 2014 | 5 | 0.030 |
Why?
|
| Floors and Floorcoverings | 1 | 2014 | 7 | 0.030 |
Why?
|
| Pets | 1 | 2014 | 9 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 972 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 682 | 0.030 |
Why?
|
| Foot | 1 | 2014 | 53 | 0.030 |
Why?
|
| Surface Properties | 1 | 2014 | 131 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1779 | 0.030 |
Why?
|
| Nose | 1 | 2014 | 94 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 2503 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2020 | 901 | 0.030 |
Why?
|
| Metagenome | 1 | 2014 | 105 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 82 | 0.030 |
Why?
|
| Quorum Sensing | 1 | 2013 | 28 | 0.030 |
Why?
|
| Hand | 1 | 2014 | 143 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1864 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 114 | 0.030 |
Why?
|
| Radiation | 1 | 2012 | 15 | 0.030 |
Why?
|
| Protective Agents | 1 | 2012 | 34 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2012 | 70 | 0.030 |
Why?
|
| Phosphates | 1 | 2012 | 161 | 0.020 |
Why?
|
| Tight Junctions | 1 | 2012 | 150 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7241 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 360 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2329 | 0.020 |
Why?
|
| Multiple Trauma | 1 | 2008 | 34 | 0.020 |
Why?
|
| Thoracic Injuries | 1 | 2008 | 38 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 171 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3024 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 199 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2008 | 148 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 846 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 1718 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 1214 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2018 | 0.010 |
Why?
|